Johnson & Johnson (NYSE:JNJ) Stake Lifted by Radnor Capital Management LLC

Radnor Capital Management LLC raised its position in Johnson & Johnson (NYSE:JNJ – Get Rating) by 0.3% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 33,071 shares of the company’s stock after purchasing an additional 100 shares during the period. Johnson & Johnson accounts for approximately 1.4% of Radnor Capital Management LLC’s portfolio, making the stock its 8th biggest holding. Radnor Capital Management LLC’s holdings in Johnson & Johnson were worth $5,927,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. TD Capital Management LLC purchased a new position in shares of Johnson & Johnson during the 3rd quarter worth $48,000. Cowa LLC purchased a new position in shares of Johnson & Johnson during the 3rd quarter worth $58,000. Legend Financial Advisors Inc. purchased a new position in shares of Johnson & Johnson during the 3rd quarter worth $59,000. Adirondack Retirement Specialists Inc. purchased a new position in shares of Johnson & Johnson during the 3rd quarter worth $67,000. Finally, Heritage Wealth Management LLC purchased a new position in shares of Johnson & Johnson during the 2nd quarter worth $84,000. Hedge funds and other institutional investors own 67.94% of the company’s stock.

Johnson & Johnson Stock Performance

Shares of Johnson & Johnson stock opened at $152.38 on Friday. Johnson & Johnson has a one year low of $150.71 and a one year high of $186.69. The company has a market cap of $396.84 billion, a PE ratio of 22.61, a P/E/G ratio of 2.65 and a beta of 0.54. The company has a debt-to-equity ratio of 0.35, a quick ratio of 0.77 and a current ratio of 0.99. The business has a 50-day simple moving average of $161.97 and a 200-day simple moving average of $167.88.

Johnson & Johnson (NYSE:JNJ – Get Rating) last announced its quarterly earnings data on Tuesday, January 24th. The company reported $2.35 EPS for the quarter, topping analysts’ consensus estimates of $2.22 by $0.13. Johnson & Johnson had a return on equity of 35.76% and a net margin of 18.90%. The business had revenue of $23.71 billion during the quarter, compared to the consensus estimate of $23.90 billion. During the same period in the previous year, the company posted $2.13 earnings per share. The business’s revenue for the quarter was down 4.4% on a year-over-year basis. On average, equities research analysts forecast that Johnson & Johnson will post 10.5 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, March 7th. Stockholders of record on Tuesday, February 21st were given a dividend of $1.13 per share. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.97%. The ex-dividend date of this dividend was Friday, February 17th. Johnson & Johnson’s dividend payout ratio is presently 67.06%.

Wall Street Analyst Weigh In

Several research firms have recently commented on JNJ. StockNews.com began coverage on Johnson & Johnson in a report on Thursday. They set a “strong-buy” rating on the stock. Guggenheim assumed coverage on Johnson & Johnson in a report on Tuesday, February 28th. They set a “neutral” rating and a $161.00 price target on the stock. Citigroup boosted their price objective on shares of Johnson & Johnson from $198.00 to $205.00 and gave the company a “buy” rating in a report on Monday, December 12th. Piper Sandler reduced their price objective on shares of Johnson & Johnson from $55.00 to $52.00 in a report on Monday, February 6th. Finally, SVB Leerink reduced their price objective on shares of Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating on the stock in a report on Friday, January 20th. Seven equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Johnson & Johnson currently has an average rating of “Moderate Buy” and a consensus target price of $174.73.

Insider Transactions at Johnson & Johnson

In related news, insider James D. Swanson sold 1,062 shares of the company’s stock in a transaction that occurred on Monday, March 6th. The stock was sold at an average price of $154.66, for a total value of $164,248.92. Following the completion of the transaction, the insider now directly owns 9,215 shares of the company’s stock, valued at $1,425,191.90. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.35% of the company’s stock.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.